RCA-two (pre- and post-filter citrate) had 99.7% dialysis completion, lowest serious clotting (5.4%), and fewer adverse events (1.8%) in high-bleeding-risk HD patients.
Does pre- and post-filter citrate anticoagulation improve circuit survival time in hemodialysis patients at high risk of bleeding?
Pre- and post-filter citrate anticoagulation is safe and improves complete dialysis rates and venous anticoagulation compared to prefilter citrate alone in high-bleeding-risk hemodialysis patients, though circuit survival time is similar.
Absolute Event Rate: 0% vs 0%
Optimal regional citrate anticoagulation (RCA) for hemodialysis (HD) in high-bleeding-risk patients remains undefined. This prospective observational cohort study included 195 high-bleeding-risk patients (481 HD sessions) allocated to three RCA groups: RCA-one (prefilter citrate only, 141 patients/337 sessions), RCA-two (pre- and post-filter citrate, 51 patients/133 sessions), and RCA+saline (prefilter citrate + post-filter saline, 3 patients/11 sessions). Primary outcome: circuit survival time; secondary outcomes: complete dialysis rate, clotting scores, and adverse events. RCA-two had the highest complete dialysis rate (99.7% vs. 97.0% RCA-one, 97.7% RCA+saline; p = .037) and lowest venous expansion chamber serious clotting (score = 3: 5.4% vs. 16.9%, 30.0%; p p p = .83). RCA-two had the lowest adverse event rate (1.8% vs. 10.8%, 11.1%; p = .001), including less hypotension (0.9% vs. 7.6%, 2.0%; p = .023) and no muscle cramps. Venous pretreatment calcium in RCA-two decreased at 2 h (p = .03) without serious electrolyte/acid-base imbalances. Circuit survival time did not differ among groups (p > .05). RCA is safe and effective for high-bleeding-risk HD patients. RCA-two (pre- and post-filter citrate) offers advantages in venous anticoagulation and safety but requires confirmation in large randomized trials.
Chen et al. (Sun,) reported a other. RCA-two (pre- and post-filter citrate) had 99.7% dialysis completion, lowest serious clotting (5.4%), and fewer adverse events (1.8%) in high-bleeding-risk HD patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: